Reconceptualizing Consent for Direct-to-Consumer Health Services

49 Pages Posted: 6 Jun 2015 Last revised: 9 Jun 2016

See all articles by Kayte Spector-Bagdady

Kayte Spector-Bagdady

University of Michigan at Ann Arbor - Medical School

Date Written: November 18, 2015

Abstract

The market for direct-to-consumer (DTC) health services continues to grow rapidly with former patients converting to customers for the opportunity to purchase varied diagnostic tests without the involvement of their clinician. For the first time a DTC genetic testing company is advertising health-related reports “that meet [Food and Drug Administration] standards for being clinically and scientifically valid.” Ethicists and regulatory agencies alike have recognized the need for a more informed transaction in the DTC context, but how should we classify a commercial transaction for something normally protected by a duty of care? How can we assure informed agreements in an industry with terms and conditions as varied as the services performed? The doctrine of “informed consent” began as an ethical construct building on the promise of beneficence in the clinical relationship and elevating the principle of autonomy — but in the DTC context should we hold providers to legal standards of informed consent and associated medical malpractice liability, or contractual obligations where consumers would seek remedy for breach?

This Article analyzes the fine balance that must be struck in an industry where companies are selling services for entertainment or non-medical purposes that possess the capacity to produce serious and disquieting medical information. It begins by reviewing current standards of consent in the clinical setting from both a legal and ethical perspective and then lays forth current standards for DTC consent using two currently controversial case studies: that of keepsake fetal ultrasound and genetic testing.

DTC keepsake ultrasound and genetic testing providers attempt to de-medicalize the devices used for these procedures from their intended medical uses to non-medical uses. But while keepsake ultrasound is marketed as “intended for entertainment purposes only,” it can provide medical information as an incidental finding. 23andMe currently purports to be the only DTC genetics service that “includes” reports that meet FDA qualifications, despite disclaimers of intent to “provide medical advice.” The attempted de-medicalization of these devices, therefore, has not been fully transformative, and DTC providers should have more robust ethical and legal duties than the average goods and services seller.

This Article delineates these responsibilities, beginning with ethical duties surrounding marketing, entering into, and providing DTC services. It then turns to the legal paradigms necessary to enable, or at least allow for, DTC providers to meet these ethical obligations. While it argues that contractual, as opposed to fiduciary, requirements are most appropriate and that waivers of liability will likely be upheld, it also advocates for a heightened expectation of disclosure during contracting.

Keywords: Direct-to-consumer; fetal ultrasound; genetic test; consent; informed consent; keepsake fetal utrasound; entertainment fetal ultrasound; 23andMe

Suggested Citation

Spector-Bagdady, Kayte, Reconceptualizing Consent for Direct-to-Consumer Health Services (November 18, 2015). American Journal of Law & Medicine, 41 (2015): 568-616, Available at SSRN: https://ssrn.com/abstract=2615316

Kayte Spector-Bagdady (Contact Author)

University of Michigan at Ann Arbor - Medical School ( email )

Ann Arbor, MI
United States

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
90
Abstract Views
651
rank
383,751
PlumX Metrics